Business and Finance

The acquisition of Cryoport’s specialty courier business is now finalized, with a value of approximately $200 million.

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.

This serialization system represents a business imperative that yields significant competitive advantages.

The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

The partnership is centered around cutting cold chain costs and emissions with smart packaging and carbon-neutral same-day delivery.

Andrew Witty resigns due to personal reasons, as Stephen Hemsley, chairman and former chief executive, will assume the position.

The financial decision is due to customer demand stemming from the reshoring of drug supply services.

The President plans to sign an executive order on Monday morning to enforce the trade clause.

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.

The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.

One expert's take on reshoring pharma manufacturing services in the US amid likely tariffs to drugs looming.

A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.

How data-driven insights can help pharma companies balance their revenue management and innovation strategies—including resource allocation, pricing, and market access.

The parties aim to create an end-to-end digital thread that links research data all the way through to life sciences manufacturing.

In a move meant to encourage domestic production, the president’s executive order features a 10% baseline tax, expected to take effect April 9.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a month, while Lilly also sells the GLP-1 via its LillyDirect platform.

CRYOPDP—centered around clinical trials, biopharma, and cell and gene therapies—augments DHL’s specialty pharma logistics expertise.

The move by the CDMO—who also houses a North American HQ in Indiana—expresses its interest in providing compliant storage and logistics solutions globally.

The Beijing location represents the sixth worldwide.

What drivers impact the differences in expenditures?

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, outlines the ways that tariffs disrupt pharma supply chains, along with how leaders can evaluate and prepare for the resulting challenges.

Why driving results from such strategies—amid industry disruption—will be critical to success.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, comments on how he envisions automation in the CAR-T manufacturing space playing a role in improving efficiency, reducing costs, and ultimately, expanding patient access.

The thermal packaging company not only bolsters its APAC presence—it also grows its influence in the life sciences’ temperature-monitoring logistics sector.

The CRDMO’s acquisition of the Baltimore plant is expected to boost its biologics presence.